GlassScriptPhysician profile
John Diakiw
NPI 1245208081
$22,888.83
in general payments reported to CMS, 2019-2025
44 companies · $3,383 in 2025
The $3,383 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,145 · 2020: $1,667 · 2021: $3,891 · 2022: $2,271 · 2023: $3,405 · 2024: $4,127 · 2025: $3,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,914.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,076.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $2,709.84 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,015.41 | 2019-2025 | Jardiance, Ofev, Tradjenta |
| Novo Nordisk INC | $1,698.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,605.71 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $1,458.51 | 2019-2025 | |
| Abbvie INC. | $1,389.91 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $1,372.19 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $756.46 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $628.39 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $619.07 | 2019-2025 | Eliquis, Camzyos |
| Esperion Therapeutics, INC. | $583.39 | 2020-2025 | Nexletol |
| Allergan, INC. | $465.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $418.03 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Sanofi-Aventis U.S. LLC | $371.84 | 2019-2023 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $304.99 | 2019-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.12 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $256.86 | 2019-2021 | |
| Abbott Laboratories | $256.01 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $192.34 | 2025 | Voquezna |
| Exact Sciences Corporation | $175.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medtronic, INC. | $150.36 | 2023 | Prestige LP Cervical Disc System |
| Dexcom, INC. | $129.91 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $129.47 | 2022 | |
| Intuitive Surgical, INC. | $128.28 | 2022 | |
| Astellas Pharma US INC | $104.81 | 2021-2022 | |
| Shield Therapeutics INC | $89.78 | 2023-2024 | Accrufer |
| Verona Pharma, INC. | $61.16 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $58.03 | 2023-2024 | |
| Axsome Therapeutics, INC. | $45.92 | 2025 | Symbravo, Auvelity |
| Biohaven Pharmaceuticals, INC. | $45.11 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $42.83 | 2019 | |
| Avanir Pharmaceuticals, INC. | $36.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.29 | 2019-2022 | |
| Abiomed | $28.73 | 2024 | Impella |
| Otsuka America Pharmaceutical, INC. | $26.29 | 2025 | Rexulti |
| Insulet Corporation | $22.15 | 2025 | Omnipod |
| Horizon Therapeutics Plc | $19.91 | 2019 | |
| Ibsa Pharma INC. | $18.52 | 2025 | Tirosint, Flector, Licart |
| Sumitomo Pharma America, INC. | $17.21 | 2025 | Gemtesa |
| Almatica Pharma LLC | $16.10 | 2022 | |
| Radius Health, INC. | $14.91 | 2023 | Tymlos |
| Sanofi Pasteur INC. | $14.28 | 2019 | |
| Organon LLC | $9.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Diakiw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.